Novel pancreatic beta cell-specific proteins: Antibody-based proteomics for identification of new biomarker candidates

Lindskog, Cecilia; Korsgren, Olle; Pontén, Fredrik; Eriksson, Jan W.; Johansson, Lars; Danielsson, Anna

doi:10.1016/j.jprot.2012.03.008

Cited by 58 publications

(54 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approaches such as proteomic and transcriptomic analyses can be used to screen pancreas cell types for unique beta cell targets [9]. Recent publications using informatics and public access databases have identified several beta cell-restricted molecular protein targets [18,19]. The small molecules or peptides that bind to these novel targets and are suitable for radiolabelling and clinical imaging applications remain to be identified.…”

Section: Principles Of Radiotracer Development For Beta Cell Massmentioning

confidence: 99%

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

et al. 2016

View full text Add to dashboard Cite

Radiotracer imaging is characterised by high in vivo sensitivity, with a detection limit in the lower picomolar range. Therefore, radiotracers represent a valuable tool for imaging pancreatic beta cells. High demands are made of radiotracers for in vivo imaging of beta cells. Beta cells represent only a small fraction of the volume of the pancreas (usually 1-3%) and are scattered in the tiny islets of Langerhans throughout the organ. In order to be able to measure a beta cell-specific signal, one has to rely on highly specific tracer molecules because current in vivo imaging technologies do not allow the resolution of single islets in humans non-invasively. Currently, a considerable amount of preclinical data are available for several radiotracers and three are under clinical evaluation. We summarise the current status of the evaluation of these tracer molecules and put forward recommendations for their further evaluation.

show abstract

Section: Principles Of Radiotracer Development For Beta Cell Massmentioning

confidence: 99%

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, it needs to be taken into consideration that the desired level of accuracy and specificity versus sensitivity may differ depending on the aim of the study. A biomarker intended to be used for labelling of beta cells in pancreas may only require absent staining in other cells of islet of Langerhans and abdominal organs adjacent to pancreas, while unspecific antibody binding in other tissues does not interfere with the result (Lindskog et al., 2012). In contrast, a potential diagnostic marker with the aim to accurately determine the origin of a metastasis tumour needs a higher level of specificity, in order to set the correct diagnosis (Gremel et al., 2014).…”

Section: Ideal Work‐flowmentioning

confidence: 99%

Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers

et al. 2014

Self Cite

View full text Add to dashboard Cite

The use of immunohistochemistry (IHC) in clinical cohorts is of paramount importance in determining the utility of a biomarker in clinical practice. A major bottleneck in translating a biomarker from bench‐to‐bedside is the lack of well characterized, specific antibodies suitable for IHC. Despite the widespread use of IHC as a biomarker validation tool, no universally accepted standardization guidelines have been developed to determine the applicability of particular antibodies for IHC prior to its use. In this review, we discuss the technical challenges faced by the use of immunohistochemical biomarkers and rigorously explore classical and emerging antibody validation technologies. Based on our review of these technologies, we provide strict criteria for the pragmatic validation of antibodies for use in immunohistochemical assays.

show abstract

“…Using a diabetic mouse model and human pancreatic tissue samples from control and T1D donors, various histological staining patterns were used to show the specificity of this antibody. Many other groups are also seeking to identify b cell biomarkers [61], as the monitoring of islet cell health and disease progression are of critical clinical importance [62].…”

Section: Cellular Regenerationmentioning

confidence: 99%

A run on the biobank

Kaddis

Pugliese

Atkinson

2015

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

Novel pancreatic beta cell-specific proteins: Antibody-based proteomics for identification of new biomarker candidates

Cited by 58 publications

References 40 publications

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers

A run on the biobank

Contact Info

Product

Resources

About